Venous Thromboembolism Therapeutics Pipeline Analysis – Collaboration, and Other Developments

Venous Thromboembolism Therapeutics Pipeline

The venous thromboembolism therapeutics pipeline is expected to witness considerable growth in the coming year due to the development of novel oral anticoagulants as a reasonable and established treatment option. The regulatory bodies are supporting the drug development process through different types of designations and funding. The pipeline is being driven by different factors such as increasing awareness regarding the venous thromboembolism therapeutics pipeline, high demand for safe, effective and affordable medications, technological advancements and increasing prevalence of the venous thromboembolism.

Explore Report at:

According to American Heart Association, Venous thromboembolism (VTE) collectively develops as a combination of deep vein thrombosis (DVT) and pulmonary embolism (PE), two life-threatening conditions. Venous thromboembolism is a common and preventable disease in which the clot formation occurs in the vein associated with Venous thromboembolism. In deep vein thrombosis, a clot formed in a deep vein, usually in the leg. Pulmonary embolism is a deep vein thrombosis clot that breaks free from a vein wall, travels to the lungs and blocks some or all of the blood supply. Blood clots in the thigh are more likely to break off and travel to the lungs than the clots in lower leg or other parts of the body.

Request for Table of Content at:

Some of the companies having a pipeline of venous thromboembolism therapeutics include Bristol-Myers Squibb Company, Pfizer, Inc., Sanofi-Aventis, Daiichi Sankyo Co. Ltd., Astellas Pharma Inc. and Johnson & Johnson.

Neuroblastoma Therapeutics Pipeline Analysis 2017 – Collaboration and Other Developments


The neuroblastoma therapeutics pipeline is expected to witness considerable growth in the future due to high prevalence of tumour in children. According to the American Cancer Society, around 7.0% of total cancer cases occurred in the age group of 0 to 14, observed as neuroblastoma, with most of the cases being reported at an age of 2 to 3 years. There are various immunotherapies and targeted drug therapies that are being developed for treatment of neuroblastoma which are expected to further lead to the growth of its pipeline in the future.

Explore Report at:

Neuroblastoma is the most common type of cancer found in children, diagnosed mostly at the age of 1 year, characterized by broad range of clinical behavior. Neuroblastoma is derived from primordial neural crest cell which ultimately present into the sympathetic ganglia and adrenal medulla. It has been stated that the chances of survival in an event free from neuroblastoma are less than 50.0%. Neuroblastoma in chest can cause wheezing, chest pain, drooping eyelids and unequal pupils. The disease usually metastasized in bone marrow, skin, liver and bones until it is diagnosed. Abdominal pain, swelling in legs and altered bowel habits are the common symptoms of abdominal neuroblastoma. Fever, shortness of breath, high blood pressure, watery diarrhea and uncontrolled eye movement are the less common symptoms of neuroblastoma. Scientist have also concluded that neuroblastoma can also occurs due to genetic mutation. The elevation of level of urinary catecholamine is the primary evidence of neuroblastoma.

Request for Table of Content at:

Some of the key players having a pipeline of neuroblastoma therapeutics include AstraZeneca Plc, Celgene Corporation, Progenics Pharmaceuticals, Inc., Novartis AG, Abbvie, Inc., MabVax Therapeutics Holdings, Inc., Pfizer Inc., Syros Pharmaceuticals, Inc., Array BioPharma, and Takeda Pharmaceutical Company Limited.

Anal Cancer Therapeutics Pipeline Analysis 2017 – Patent, Designation and Development

Anal Cancer Therapeutics Pipeline Analysis

Anal cancer therapeutic pipeline analysis is expected to increase owing to increasing incidence globally, majorly in older adults. Major factors driving towards the pipeline growth for anal cancer include growing rate of sexually transmitted diseases and aging population. Additionally, increasing awareness regarding health issues among people is another major factor fueling the pipeline growth for anal cancer. According to American Cancer Society, the prevalence of anal cancer has increased with increasing older population. Around 8,200 new cases for anal cancer are estimated to be diagnosed with in 2017, in the U.S., out of which 5,250 cases are estimated to be present in women and 2,950 are estimated to be present in men. The disease affecting females more commonly as compared to the males.

Explore Report at:

Merck Sharp & Dohme Corp., is in the process of introducing a compound, Pembrolizumab. The compound is in Phase II clinical stage, and is being tested for its safety and efficacy in a 36-week trial. Pembrolizumab is a programmed cell death 1 ligand 2 protein inhibitor and is given intravenouly. Advaxis, Inc., is also testing on safety and efficacy of compound – ADXS11-001, which is in Phase II stage of development. Eli Lilly and Company, is developing a compound Prexasertib which is being tested for its safety and efficacy for patients diagnosed with anal squamous cell carcinoma. Prexasertib is a checkpoint kinase 1 inhibitor. Oryx GmbH & Co. KG, is developing a compound, P16_37-63 peptide combined with Montanide ISA-51 VG, which is in Phase I clinical development stage. P16_37-63 peptide combined with Montanide ISA-51 VG is an immunostimulant and is being developed with subcutaneous route of administration. ISA Pharmaceuticals B.V., is in the process of developing a compound HPV-16 vaccine, which is an immunostimulant and is currently in Phase I/II. It is therapeutic vaccination against human papillomavirus type 16 for the treatment of anal intraepithelial neoplasia in HIV positive men.

Browse Other Related Report at:

Some of the key having a pipeline of anal cancer therapeutics include Advaxis, Inc., Amgen Inc., Atara Biotherapeutics Inc, Bayer AG, Cell Medica Ltd., Eli Lilly and Company, Genticel S.A., ISA Pharmaceuticals B.V., Merck & Co Inc, Millennium Pharmaceuticals Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., Oryx GmbH & Co. KG, PDS Biotechnology Corporation, Sun Pharma Advanced Research Company Ltd., Taiwan Liposome Company, Ltd.

Cystic Fibrosis Therapeutics Pipeline Analysis 2017

Increasing prevalence of cystic fibrosis being witnessed mostly in Europe and the U.S. due to lack of awareness among people towards genetic diseases. In addition, some other factors contributing to the increasing occurrence of cystic fibrosis disease include smoking during pregnancy, hereditary disorder, and premature mortality of infants. The therapeutic pipeline of this particular disease is expected to grow in the future on account of major pharmaceutical companies betting involved in research & development of personalized medicines for the treatment of cystic fibrosis. In addition, various awareness programs and seminar on Cystic fibrosis are also being organized by the government, so as to make the people aware about the disease, its effects, and the possible treatments. Cystic fibrosis is the genetic disorder, which mainly affects the lungs. It is caused due to mutation in CFTR (cystic fibrosis transmembrane conductance regulator) gene. According to Center for Disease Control and Prevention, more than 30,000 people in the U.S. are infected with cystic fibrosis, while ratio of the same in newborn babies in Europe was recorded to be around one out of every 2,000 newborn babies.

Explore Report at:

Cystic fibrosis is an autosomal recessive disorder, which affects the digestive, respiratory & the reproductive system of the body. Cystic fibrosis involves the production of thick mucus in the lungs and leads to fatal infection. Mucus, a slippery material used to protect respiratory as well as digestive system, becomes abnormally thick in case of cystic fibrosis and causes damage to the lungs. The patients suffering from cystic fibrosis usually face the problem of indigestion. Major symptoms associated with cystic fibrosis or abdominal distention are loss of appetite, difficulty in breathing, gastrointestinal bleeding, persistent coughing, weight loss, bulky stool, excessive sweating, etc.

Request for Table of Content at:

Some of the companies having a pipeline of Crohn’s disease therapeutic include Galapagos NV, Prometic Biosciences, ProQR therapeutics, Verona pharmaceuticals, Proteostasis therapeutics, Pfizer Inc., Amgen Inc., Novartis AG, Gilead sciences etc.

Small Lymphocytic Lymphoma Therapeutics Pipeline Analysis 2017

The rising prevalence of small lymphocytic lymphoma is responsible for the upsurge in research and development of therapeutics that can control progression of the disease, and in turn lead to discovery of new targets that would assist in curing cancer. Increasing adoption of unhealthy lifestyle, unchecked use of pesticides in cultivating crops and fruits along with intake of unhygienic food items causes virus infection such as Hepatitis C and Epstein-Barr virus, which may trigger the incidence of small lymphocytic lymphoma. Therefore, the therapeutic pipeline of small lymphocytic lymphoma is increasing in consequent manner. Consequently, increase in healthcare awareness among consumers is further supplementing growth of small lymphocytic lymphoma therapeutics pipeline.

Explore Report at:

Small lymphocytic lymphoma is a sort of non-Hodgkin lymphoma, which generally affects the B-lymphocytes of the immune system that are present in the lymphoid tissue such as tonsils and spleen, and lymph nodes. However, small lymphocytic lymphoma has many similarities with chronic lymphocytic leukaemia, which acts on the B-lymphocytes that are present in the bone marrow and blood. The observed symptoms of small lymphocytic lymphoma are loss of appetite, night sweats, fever, fatigue, weight loss, etc.

In October 2016, Janssen Research & Development, LLC started a Phase II study of the combination of Ibrutinib, which is bruton’s tyrosine kinase (BTK) inhibitor; and Venetoclax, which is a BCL-2 inhibitor and an antiapoptotic protein, in subjects undergoing the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. This study is expected to be completed by September 2021. In December 2013, Verastem Inc., started a Phase III extension study of Duvelisib and Ofatumumab in patients suffering from chronic lymphocytic leukemia/ small lymphocytic lymphoma, previously enrolled in the study IPI-145-07. This study is expected to be completed by December 2018. In January 2017, Genentech Inc., started a Phase II study of combination of drugs – Atezolizumab, with Obinutuzumab and Ibrutinib, for the treatment of small lymphocytic lymphoma. This study is expected to be completed by January 2021.

Request for table of Content at:

Some of the companies having a pipeline of small lymphocytic lymphoma therapeutics include Janssen Research & Development, LLC, Boehringer Ingelheim GmbH, Verastem, Inc., Celgene Corporation, Shanghai Zhangjiang Biotechnology Limited Company, TG Therapeutics, Inc.

Myelofibrosis Therapeutics Pipeline Analysis 2017

Myelofibrosis Therapeutics Pipeline Analysis

Myelofibrosis is a disease characterized by the build-up of scar tissue in the bone marrow, which leads to genetic mutation in a person’s body. The myelofibrosis therapeutics pipeline is anticipated to increase with the growing need to develop a cure for the problem, and is noticed in approximately one in 500,000 people, in the U.S., usually in the age group of 50 to 80 years, as per the as data provided by U.S. national Library of Medicine. It is a rare form of disease and also happens to patients with thrombocythemia and polycythemia. Moreover, the future developments in therapies are expected to shoot-up.

Explore Report at:

According to National Center for Advancing Translational Sciences, myelofibrosis is disorder of bone marrow, in which bone marrow is replaced by fibrous tissues. In myelofibrosis, bone marrow cannot produce sufficient blood cells and platelets, which leads to weakness, anemia, fatigue and sometimes swelling of spleen and liver. Reduction in number of platelets can cause bleeding and bruising. This condition is also called extramedullary haematopoiesis. The genes of the stem cells such as, JAK2, MPL, CALR, and TET2 genes undergo mutation in somatic stem cells but, the condition is uninherited. Treatments for the problem include chemotherapy, radiation therapy, blood transfusion and surgery.

Request for Table of Content at:

In November 2013, Baxter International Inc. entered into a licensing agreement with Cell Therapeutics, Inc., to develop and commercialize – pacritinib. Pacritinib is a novel investigational JAK2/FLT3 inhibitor with activity against genetic mutations linked to myelofibrosis, leukemia and certain solid tumors. Pacritinib is currently in Phase II clinical development in patients having chronic malignant bone marrow disorder, myelofibrosis.

Some of the companies having a pipeline of myelofibrosis therapeutics include Incyte Corporation, Novartis AG, Pfizer, Inc., Constellation Pharmaceuticals, Inc., GlaxoSmithKline Plc, Geron Corporation, Baxter International Inc.

Polycystic kidney disease Therapeutics Pipeline Analysis 2017

Polycystic kidney disease Therapeutics Pipeline

The platform of new drugs for the polycystic kidney disease is increasing on account of less number of drugs available for treatment of the disease. Polycystic kidney disease is a form of rare disease and the drugs which are available for treatment, have an adverse effect on the health of patients. Currently, the prevalence of polycystic kidney disease in the U.S. ranges from 1 in 400 to 1 in 1000 which resulted in end stage renal disease by the age of 53. Around 600,000 patients are suffering from renal disease, out of which 2,000 patients start a renal replacement therapy every year. Increasing awareness in health-related issues is another factor responsible for the growth of polycystic kidney disease therapeutics pipeline.

Explore Report at:

Polycystic kidney disease is a disease which affects kidney along with other organs, in which development of cyst interrupts the ability to filter the waste products from blood. Enlargement of cyst may lead to kidney failure which can in turn impact other organs. Polycystic kidney disease is mostly related to high blood pressure, blood in urine, pain in back, kidney stones and heart valve abnormalities. People with polycystic kidney disease are at a risk of developing aneurysm in aorta or in blood vessels in base of the brain. Polycystic kidney disease is of two types as, autosomal dominant polycystic kidney disease, which begins in adulthood and autosomal recessive polycystic kidney disease. Autosomal dominant polycystic kidney disease can also be categorised as type 1 and type 2 subjected to genetic cause. The autosomal recessive polycystic kidney disease is a very rare and lethal form of disease, and its symptoms start appearing during birth or infancy. Polycystic kidney disease occurs mainly due to mutations in PKD1, PKD2 and PKHD1 genes.

Request for Table of Content at:

Some of the companies having a pipeline of polycystic kidney disease therapeutics include Otsuka Pharmaceutical Co., Ltd., Alexion Pharmaceuticals Inc, Kyowa Hakko Kirin Co., Ltd., Catalyst Biosciences, Inc., Amgen, Inc., Angion Biomedica Corporation, Amyndas Pharmaceuticals LLC, Apellis Pharmaceuticals, Inc, Biogen, Inc, Astellas Pharma, Inc., Corline Biomedical AB, CSL Limited, Digna Biotech, S.L., GlaxoSmithKline Plc, Grifols, S.A.

Multiple Sclerosis Therapeutics Pipeline Analysis 2017 – Clinical Trials & Results, Patent

Multiple Sclerosis Therapeutics Pipeline Analysis

Multiple sclerosis therapeutic pipeline is expected to grow in future on account of increasing demands of drugs which can completely overcome the rising prevalence of the disease. Currently, multiple sclerosis is mainly impacting regions North America and Europe, some of the other geographies impacted with the disease include Eastern Asia and Sub-Saharan Africa, at very low rate. Major factors driving the growth of pipeline for multiple sclerosis are increasing incidences of multiple sclerosis, stress conditions related to depression, decrease in life expectancy in patients with multiple sclerosis and increasing awareness of health issues.

Explore Report at:

Multiple sclerosis is an unpredictable disease of nervous system which leads to devastation and disabling communication between brain and other parts of the body. It was also considered as an autoimmune disease in which immune system attacks its own tissues. It mainly causes the disruption of myelin sheath in nervous system and mainly occurs between the age of 20 to 40. Some of the initial symptoms of the disease include, blurred vision or even blindness in one eye, muscle weakness, difficulty in coordination which further leads to the impaired walking and standing. Some patients also experience pain, tremor, dizziness and sometimes hearing loss. Some of the other problems related to the disease include mental and psychological problems such as lack of attention, concentration and poor memory and judgements.

Request for Table of Content at:

Sanofi Genzyme collaborated with John Hopkins School of Medicine for development of novel strategies. ChemoCentryx and Forest Laboratories entered into a collaboration for the development of CCR1 receptor antagonist for multiple sclerosis therapeutics. Numares AG and Oxford University are in the process of entering into a collaboration for the development of in-vitro diagnostic test to improve therapeutic decision making for patients with multiple sclerosis, with the help of magnetic group signalling technology.

Some of the companies having a pipeline of the growth hormone deficiency therapeutics include Teva Pharmaceuticals, Biogen Idec, Bayer Healthcare, Sanofi-Aventis, Pfizer, Merck, and Novartis AG.

Hereditary Angioedema Therapeutics Pipeline Analysis, 2017 – Clinical Trials & Results, Collaboration and Other Developments

The pipeline of hereditary angioedema is increasing on account of rising instances of angioedema, globally. Currently, an estimated prevalence of hereditary angioedema in the world is 1 in 10,000 to 1 in 150,000. Major factors driving the growth of pipeline for hereditary angioedema include increasing prevalence of attacks of angioedema and rising cases of angioedema in association with other conditions like significant hypotension resulting from abdominal attacks, low market penetration as very less number of companies are making an analog and increasing awareness of health issues. The impairment in quality of life and rising medical cost also act as the driving factor for the hereditary angioedema pipeline.

Explore Report at:

Angioedema can be defined as swelling of mucosal or skin tissues, which leads to extravasation of fluid into the interstitium and loss of vascular integrity. There are two basic types of angioedema, histaminergic angioedema and non-histaminergic angioedema. Histaminergic is basically associated with urticaria. Non-histaminergic angioedema is usually not associated with urticaria, and is only mediated by bradykinin. The non-histaminergic angioedema is further divided in four categories namely, angiotensin-converting enzyme (ACE) inhibitor-associated angioedema, hereditary angioedema (HAE), idiopathic angioedema and acquired angioedema. Hereditary angioedema is symptomatized as episodic swelling disorder and arises from autosomal dominant trait. Clinical features include nonpitting edema of external body surfaces, abdominal pain, swelling of the extremities and swelling of the mouth and throat, which can lead to asphyxiation.

Request for table of Content at:

Some of the companies having a pipeline of hereditary angioedema therapeutics include BioCryst Pharmaceuticals, Inc., CSL Limited, Dyax Corp., Cevec Pharmaceuticals GmbH, Global Blood Therapeutics, Inc., Isis Pharmaceuticals, Inc., iBio, Inc. Pharming Group N.V., Ra Pharmaceuticals, Inc., Shire Plc.

Cluster Headache Therapeutics Pipeline Analysis 2017 – Collaboration and Other Developments

Cluster Headache Therapeutics Pipeline Analysis

Rapidly increasing pace of life, change in lifestyle, higher stress levels, etc., are few of the major factors to which the increasing prevalence of cluster headache scan be attributed. Further, unhealthy dietary intake, smoking, alcoholconsumption and growing levels of pollutionare few other factors which are expected to fuel the incidence of cluster headache problem. The Therapeutic pipeline of cluster headache is expected to grow in future with the participation of various pharmaceutical companies that are focusing on developing novel drugs for curing the problem of cluster headache. As per WHO, problem of cluster headache is more common in men, as compared to women, and mostly in people in the age group of 20 to 40 years. According to a recently published NCBI paper, one of every 1,000 adults in the U.S. experiences the problem of cluster headache. In spite of the problem of cluster headache being very common, it has mostly been under-recognized and has been overlooked.

Explore Report at:

Cluster headache, also called ashistamine headache, is a primary headachedisorder of the nervous system, and is a headache of constant nature, experienced over a prolonged period of time, occurring mostly at night during sleep. According to the studies conducted by International Headache society (IHS), during cluster headache the patient experiences very severe pain, which occurs for duration of 15 to 180 minutes, once a day. Lacrimation, facial sweating, eyelid edema, restlessness, runny nose, rhinorrhea, ptosis, one-sided pain, nasal congestion, miosis & conjunctivitis, are few of the symptoms ofdiagnosing cluster headache.

Request for Table of Content at:

Some of the companies having a pipeline of cluster headache therapeutics include Eliy-lilly& Company, Teva pharmaceuticals industries Ltd, Winston laboratories,Gilead Sciences, Inc., Galapagos NV, Astellas Pharma, Abbvie, Inc., Bexalta US, Inc., Optimer pharmaceutical LLC.